Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2Completed 2

Sponsor Class

NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 10Tumor-Agnostic 4Gynecologic 2Genitourinary 2Sarcoma 1Other solid neoplasm 1

Conditions

Uterine Cervical Neoplasms 1Endometrial Adenocarcinoma 1

Interventions

Paclitaxel 264Carboplatin 246Cisplatin 153Bevacizumab 104Gemcitabine 78Topotecan 77liposomal doxorubicin 67pembrolizumab 60Docetaxel 56Cyclophosphamide 50Taxes 48Radiotherapy 44olaparib 43Surveys and Questionnaires 43Doxorubicin 43Filgrastim 42Brachytherapy 37Drug Therapy 31niraparib 28Blood Specimen Collection 28Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 26human papillomavirus vaccine, L1 type 16, 18 24Peripheral Blood Stem Cell Transplantation 23atezolizumab 22Oxaliplatin 22Pemetrexed 21Nivolumab 21Hyperthermic Intraperitoneal Chemotherapy 21Etoposide 21Immunoglobulin G 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × brivanib × Gynecologic × Clear all
NCT01267253 2019-03-20

Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer

GOG Foundation

Phase 2 Completed
31 enrolled 9 charts
Gynecologic

Uterine Cervical Neoplasms

NCT00888173 2017-12-06

Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer

GOG Foundation

Phase 2 Completed
45 enrolled 10 charts
GenitourinaryGynecologic

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡